Avalo Therapeutics CEO Peter Greenleaf's 2018 pay jumps 17,372% to $5.1M
Avalo Therapeutics reports 2018 executive compensation
By ExecPay News
Published: June 19, 2019
Avalo Therapeutics reported fiscal year 2018 executive compensation information on June 19, 2019.
In 2018, seven executives at Avalo Therapeutics received on average a compensation package of $1.1M, a 300% increase compared to previous year.
Average pay of disclosed executives at Avalo Therapeutics
Peter Greenleaf, Chief Executive Officer, received $5.1M in total, which increased by 17,372% compared to 2017. 50% of Greenleaf's compensation, or $2.6M, was in option awards. Greenleaf also received $360K in bonus, $456K in salary, $1.7M in stock awards, as well as $10K in other compensation.
Mariam E. Morris, Chief Financial Officer, received a compensation package of $687K, which increased by 116% compared to previous year. 49% of the compensation package, or $336K, was in other compensation.
Joseph M. Miller, Chief Financial Officer, earned $673K in 2018.
James A. Harrell, Jr, Executive Vice President, Marketing and External Communications, received $622K in 2018.
Pericles Calias, Chief Scientific Officer, earned $351K in 2018.
Robert C. Moscato, Jr, Chief Operating Officer, received $271K in 2018, which increases by 983% compared to 2017.
Simon Pedder, Chairman, earned $28K in 2018.
Related executives
Peter Greenleaf
Avalo Therapeutics
Chief Executive Officer
Joseph Miller
Avalo Therapeutics
Chief Financial Officer
James Harrell
Avalo Therapeutics
Executive Vice President, Marketing and External Communications
Robert Moscato
Avalo Therapeutics
Chief Operating Officer
Mariam Morris
Avalo Therapeutics
Chief Financial Officer
Simon Pedder
Avalo Therapeutics
Chairman
Pericles Calias
Avalo Therapeutics
Chief Scientific Officer
You may also like
Source: SEC filing on June 19, 2019.